Clinical trial NCT01468792: Hemodynamic Changes in Connective Tissue Disease
Official title: Hemodynamic Changes in Connective Tissue Disease
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Systemic Sclerosis
Keywords: systemic sclerosis
pulmonary arterial hypertension
Lead sponsor: Medical University of Graz
Sponsor class: OTHER
First posted: 2011-11-09
Enrollment: 85
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: PROSPECTIVE
Sampling method: PROBABILITY_SAMPLE
Study population: patients with known systemic sclerosis and without known pulmonary hypertension

Brief summary: The study serves the identification of early forms of pulmonary arterial hypertension (PAH) in connective tissue disease and the hemodynamic follow-up of the investigated patients. The basic hypothesis is that PAH may start with a remodeling of small pulmonary arteries, which leads to a stiffening of the vessels, indicated by the inability to vasodilatation and thus a disproportional increase in pulmonary pressure during exercise. Recent studies have shown that a proportion of such patients may develop manifest PAH within a few years. The early identification of these patients and the understanding of the natural course of the disease may improve prognosis. The aim of the present study is to investigate hemodynamic and clinical changes in patients with connective tissue disease in a time interval of 3-5 years with a focus on the development of pulmonary hypertension.


Eligibility criteria: Inclusion Criteria:

* Informed consent
* Patients with systemic sclerosis, mixed connective tissue disease, (systemic lupus erythematodes) SLE or overlap syndrome
* Existing exercise Doppler echocardiography or/and right heart catheterization 3-5 years before inclusion

Exclusion Criteria:

* - Severe lung or bronchial disease (FEV1 \<60%)
* Systolic LV dysfunction (LVEF \<50%) or diastolic dysfunction \> grade I
* Valvular defect \> grade I (except for tricuspid- or pulmonary insufficiency)
* Uncontrolled systemic arterial hypertension (at rest \>150 mmHg systolic or 95 mmHg diastolic)
* Uncontrolled ventricular arrhythmias
* Uncontrolled bradycardia or tachycardia supraventricular arrhythmias
* Myocardial infarction within the last 12 months
* Pulmonary embolism within the last 12 months
* Relevant changes in hemodynamic therapy or major surgery within the last 12 weeks
* Musculoskeletal or peripheral vessel disorders which complicates an ergometry

Primary outcomes:
measure: systolic pulmonary pressure at 50 W
timeFrame: 3-5 years
Secondary outcomes:
measure: peak (oxygen uptake) VO2
timeFrame: 3-5 years
Other outcomes:
Locations:
city: Graz
country: Austria
facility: Medical University of Graz / Pulmonology
Study officials:
affiliation: Medical University of Graz
name: Horst Olschewski, MD
role: PRINCIPAL_INVESTIGATOR
References:
citation: Kovacs G, Avian A, Wutte N, Hafner F, Moazedi-Furst F, Kielhauser S, Aberer E, Brodmann M, Graninger W, Foris V, Olschewski A, Olschewski H. Changes in pulmonary exercise haemodynamics in scleroderma: a 4-year prospective study. Eur Respir J. 2017 Jul 13;50(1):1601708. doi: 10.1183/13993003.01708-2016. Print 2017 Jul.